In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Excerpts from recent editorials in the United States and abroad: ___ Jan. 26 The Washington Post on Trump's “energy emergency” Oil and gas production in the United States is hitting record highs, ...

72 hr Manufacturer Insulin as part (rDNA origin) injection Novolog (Novo Nordisk) 28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi ...

A JAMA Network study found that, despite insulin product price increases, the manufacturers’ share ... how it would cut the list price of its Lantus product by 78%, as well as establishing ...

Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...

If approved as a biosimilar, Semglee will be established as the first direct competitor of Lantus, giving providers ... be an important turning point for manufacturers, such as Boehringer ...

Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...

Today of course most robotic manufacturers are focused on building tools for labor: warehousing, logistics, manufacturing. Just recently we’ve seen Digit by Agility Robotics get a paying gig ...

However, it's crucial to note that applications must be made through energy suppliers, not the DWP, who then pay the money directly to the energy provider, not the claimant. Changes to eligibility ...